Infectious Disease · 1996
Highly Active Antiretroviral Therapy (HAART) and the Vancouver protease-inhibitor combination era
Through the early 1990s, HIV treatment meant nucleoside reverse transcriptase inhibitors given in mono or dual combinations that reliably delayed disease progression but did not halt it. Viral resistance emerged within months in most patients, CD4 counts eventually declined, and the clinical trajectory was predictable. AIDS wards in large urban hospitals were full and remained so. The approval of saquinavir in December 1995 introduced the protease inhibitor class, but how aggressively to deploy it and in what combinations remained unsettled.
At the XI International AIDS Conference in Vancouver in July 1996, David Ho and colleagues at the Aaron Diamond AIDS Research Center in New York presented viral dynamics data and early clinical results showing that combining a protease inhibitor with two nucleoside drugs could drive plasma HIV RNA below the limit of detection. The biological rationale was Ho's own: HIV replicated at enormous daily rates, and suppressing it required hitting multiple targets simultaneously to prevent mutant escape. Julio Montaner of the BC Centre for Excellence in HIV/AIDS argued forcefully at the same conference for universal access to triple therapy. The concept that came out of Vancouver was soon called highly active antiretroviral therapy.
The clinical impact appeared quickly. AIDS deaths in the United States, which had been climbing for fifteen years, fell by roughly half between 1996 and 1997. Hospitalizations dropped sharply. The change was visible in the data before any controlled trial confirmed it, because the effect size was large enough to be apparent in surveillance numbers.
The ACTG 320 trial, published in the New England Journal of Medicine in 1997, provided the controlled evidence. Roy Gulick led the study, which enrolled 1,156 patients with CD4 counts below 200 and randomized them to indinavir plus two nucleosides versus two nucleosides alone. Progression to AIDS or death fell from 11 percent to 6 percent, and mortality from 3.1 percent to 1.4 percent, in a trial stopped early by the data safety monitoring board because the benefit was already decisive at a planned interim analysis.
Adherence proved to be the critical variable that determined whether durable suppression was achievable. Patients who took more than 95 percent of doses achieved and maintained undetectable viral loads; those with lower adherence selected resistant virus and eventually failed. That finding drove the development of fixed-dose combinations and ultimately once-daily single-tablet regimens, which were available by the mid-2000s. The Vancouver conference marked the moment the goal of treatment shifted from delaying progression to preventing it entirely.
Key People
- David Ho — Virologist whose data on combination therapy drove the Vancouver consensus
- Julio Montaner — Clinical researcher, advocate for universal triple-drug therapy
- Roy Gulick — Principal investigator, ACTG 320 trial
- Martin Markowitz — Aaron Diamond researcher who contributed viral dynamics data presented at Vancouver
N Engl J Med, 1997 (ACTG 320); Vancouver XI Intl AIDS Conf, 1996
Related landmarks
- 1997 · ACTG 320: Triple-Drug Combination Antiretroviral Therapy (Infectious Disease)
- 1987 · AZT (Zidovudine) Trial for AIDS (Infectious Disease)
- 1987 · Haemophilus influenzae type b (Hib) conjugate vaccine (Infectious Disease)
- 2006 · FUTURE / Quadrivalent HPV Vaccine Efficacy Trials (Infectious Disease)